scholarly journals Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2

2021 ◽  
pp. annrheumdis-2021-221248
Author(s):  
Marcella Visentini ◽  
Laura Gragnani ◽  
Stefano Angelo Santini ◽  
Teresa Urraro ◽  
Annalisa Villa ◽  
...  
Keyword(s):  
Mixed Cryoglobulinaemia

Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study

2014 ◽  
Vol 13 (6) ◽  
pp. 609-614 ◽  
Author(s):  
Giuseppe Monti ◽  
Francesco Saccardo ◽  
Laura Castelnovo ◽  
Paola Novati ◽  
Salvatore Sollima ◽  
...  
Keyword(s):  
Population Based ◽  
Mixed Cryoglobulinaemia ◽  
Population Based Survey

scholarly journals Parvovirus B19 infection, hepatitis C virus infection, and mixed cryoglobulinaemia

1998 ◽  
Vol 57 (7) ◽  
pp. 422-424 ◽  
Author(s):  
P. Cacoub ◽  
N. Boukli ◽  
P. Hausfater ◽  
A. Garbarg-Chenon ◽  
P. Ghillani ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Parvovirus B19 ◽  
Hepatitis C Virus Infection ◽  
Parvovirus B19 Infection ◽  
Mixed Cryoglobulinaemia

scholarly journals Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer

Rheumatology ◽  
2018 ◽  
Vol 57 (10) ◽  
pp. 1870-1871 ◽  
Author(s):  
Marcella Visentini ◽  
Luca Quartuccio ◽  
Martina Del Padre ◽  
Stefania Colantuono ◽  
Ylenia A Minafò ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Mixed Cryoglobulinaemia

T Cell Defect in Essential Mixed Cryoglobulinaemia

1979 ◽  
Vol 59 (3) ◽  
pp. 308-314 ◽  
Author(s):  
P.L. Meroni ◽  
G.F. Ciboddo ◽  
Gisella Colombo ◽  
Paola Bonara ◽  
F. Invernizzi
Keyword(s):  
T Cell ◽  
Mixed Cryoglobulinaemia ◽  
Cell Defect

scholarly journals IgM and IgG antibodies to hepatitis C virus in patients with mixed cryoglobulinaemia

2008 ◽  
Vol 94 (2) ◽  
pp. 313-316 ◽  
Author(s):  
A. L'ABBATE ◽  
S. CUTRUPI ◽  
M. ROGNETTA ◽  
C. FABIANO ◽  
A. CRAXI
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Igg Antibodies ◽  
Mixed Cryoglobulinaemia

scholarly journals Structural and Functional Characterization of Plasma Fibronectin in Patients with Essential Mixed Cryoglobulinaemia

1992 ◽  
Vol 30 (8) ◽  
Author(s):  
V. Toschi ◽  
G. F. Fiorini ◽  
Adele Motta ◽  
C. Castelli ◽  
Maria Grazia Gagliano ◽  
...  
Keyword(s):  
Functional Characterization ◽  
Plasma Fibronectin ◽  
Mixed Cryoglobulinaemia

scholarly journals Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective study

2020 ◽  
Vol 26 (3) ◽  
pp. 366-372 ◽  
Author(s):  
Y.-T. Cheng ◽  
J.-S. Cheng ◽  
C.-H. Lin ◽  
T.-H. Chen ◽  
K.-C. Lee ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Prospective Study ◽  
Rheumatoid Factor ◽  
Immunoglobulin M ◽  
Mixed Cryoglobulinaemia

scholarly journals Direct-acting antiviral therapy improves kidney survival in hepatitis C virus–associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study

2020 ◽  
Author(s):  
Ana Pérez de José ◽  
Javier Carbayo ◽  
Anna Pocurull ◽  
Teresa Bada-Bosch ◽  
Clara Maria Cases Corona ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Treatment ◽  
Antiviral Agents ◽  
Direct Acting Antiviral ◽  
Primary Endpoints ◽  
Kidney Involvement ◽  
Before And After ◽  
Mixed Cryoglobulinaemia ◽  
Direct Acting

Abstract Background Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC. Methods The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological and virological responses after antiviral treatment. Results Patients were divided into three groups based on the treatment received: treatment with DAAs (n = 100) treatment with interferon (IFN) and ribavirin (RBV) (n = 24) and no treatment (n = 15). Patients were followed up for a median duration of 138 months (interquartile range 70–251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence interval (CI) 0.04–0.40]; P < 0.001} and improved kidney survival [HR 0.10 ( 95% CI 0.04–0.33); P < 0.001]. Conclusions Results from the RENALCRYOGLOBULINEMIC study indicated that DAA treatment in patients with HCV-MC improves kidney survival and reduces mortality.

Interferon alfa in leukocytoclastic vasculitis, mixed cryoglobulinaemia, and chronic hepatitis C

The Lancet ◽  
1993 ◽  
Vol 341 (8844) ◽  
pp. 561-562 ◽  
Author(s):  
Robert Zimmermann ◽  
Volker König ◽  
Jürgen Bauditz ◽  
Uwe Hopf
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Leukocytoclastic Vasculitis ◽  
Interferon Alfa ◽  
Mixed Cryoglobulinaemia
Sign in / Sign up

Export Citation Format

Share Document